Xenon Pharmaceuticals Inc
XENE44.840USD
-0.170-0.38%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
3.46BMarket Cap
LossP/E TTM
More Details of Xenon Pharmaceuticals Inc Company
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Xenon Pharmaceuticals Inc Info
Ticker SymbolXENE
Company nameXenon Pharmaceuticals Inc
IPO dateOct 17, 2014
CEOMortimer (Ian C)
Number of employees316
Security typeOrdinary Share
Fiscal year-endOct 17
Address3650 Gilmore Way
CityVANCOUVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV5G 4W8
Phone16044843300
Websitehttps://www.xenon-pharma.com/
Ticker SymbolXENE
IPO dateOct 17, 2014
CEOMortimer (Ian C)
Company Executives of Xenon Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
-55.39%
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
20.30K
-55.39%
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Canada
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
Other
69.17%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.09%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.40%
BlackRock Institutional Trust Company, N.A.
5.25%
Janus Henderson Investors
5.10%
Other
69.17%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
48.11%
Investment Advisor
33.86%
Hedge Fund
25.98%
Research Firm
1.49%
Private Equity
1.01%
Sovereign Wealth Fund
0.82%
Pension Fund
0.75%
Bank and Trust
0.40%
Individual Investor
0.11%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
446
85.67M
110.86%
-494.45K
2025Q2
418
85.39M
111.27%
+856.94K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
6.40M
8.3%
+244.00K
+3.96%
Jun 30, 2025
Avoro Capital Advisors LLC
5.40M
7%
-341.67K
-5.95%
Jun 30, 2025
Driehaus Capital Management, LLC
4.34M
5.62%
-249.21K
-5.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.12M
5.34%
+3.47M
+534.85%
Jun 30, 2025
Janus Henderson Investors
3.58M
4.64%
+252.64K
+7.60%
Jun 30, 2025
Wellington Management Company, LLP
2.17M
2.82%
-1.61M
-42.61%
Jun 30, 2025
Braidwell LP
3.61M
4.68%
+895.15K
+33.03%
Jun 30, 2025
Capital International Investors
3.18M
4.13%
+92.82K
+3.01%
Jun 30, 2025
Commodore Capital LP
3.02M
3.92%
+700.00K
+30.11%
Jun 30, 2025
Fidelity Institutional Asset Management
2.48M
3.22%
+352.87K
+16.57%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.41%
ALPS Medical Breakthroughs ETF
1.35%
Goldman Sachs Future Health Care Equity ETF
1.13%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
0.8%
JPMorgan Fundamental Data Science Small Core ETF
0.57%
JPMorgan Healthcare Leaders ETF
0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.45%
ProShares Ultra Nasdaq Biotechnology
0.42%
Invesco Nasdaq Biotechnology ETF
0.32%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.41%
ALPS Medical Breakthroughs ETF
Proportion1.35%
Goldman Sachs Future Health Care Equity ETF
Proportion1.13%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.8%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.57%
JPMorgan Healthcare Leaders ETF
Proportion0.53%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.45%
ProShares Ultra Nasdaq Biotechnology
Proportion0.42%
Invesco Nasdaq Biotechnology ETF
Proportion0.32%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Xenon Pharmaceuticals Inc?
The top five shareholders of Xenon Pharmaceuticals Inc are:
Fidelity Management & Research Company LLC holds 6.40M shares, accounting for 8.30% of the total shares.
Avoro Capital Advisors LLC holds 5.40M shares, accounting for 7.00% of the total shares.
Driehaus Capital Management, LLC holds 4.34M shares, accounting for 5.62% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.12M shares, accounting for 5.34% of the total shares.
Janus Henderson Investors holds 3.58M shares, accounting for 4.64% of the total shares.
Fidelity Management & Research Company LLC holds 6.40M shares, accounting for 8.30% of the total shares.
Avoro Capital Advisors LLC holds 5.40M shares, accounting for 7.00% of the total shares.
Driehaus Capital Management, LLC holds 4.34M shares, accounting for 5.62% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.12M shares, accounting for 5.34% of the total shares.
Janus Henderson Investors holds 3.58M shares, accounting for 4.64% of the total shares.
What are the top three shareholder types of Xenon Pharmaceuticals Inc?
The top three shareholder types of Xenon Pharmaceuticals Inc are:
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
Driehaus Capital Management, LLC
Fidelity Management & Research Company LLC
Avoro Capital Advisors LLC
Driehaus Capital Management, LLC
How many institutions hold shares of Xenon Pharmaceuticals Inc (XENE)?
As of 2025Q3, 446 institutions hold shares of Xenon Pharmaceuticals Inc, with a combined market value of approximately 85.67M, accounting for 110.86% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.41%.
What is the biggest source of revenue for Xenon Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Xenon Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
